<DOC>
	<DOCNO>NCT02586389</DOCNO>
	<brief_summary>This specimen collection design obtain whole blood tumor tissue subject diagnose cancer purpose development noninvasive liquid biopsy assay use next generation sequencing ( NGS ) .</brief_summary>
	<brief_title>Specimen Collection From Patients With Non-Hematologic Cancer Use Development Liquid Biopsy Assay</brief_title>
	<detailed_description>This non-significant risk multicenter , longitudinal specimen collection study . At Baseline Visit , whole blood collect pair either previously collect tumor biopsy tissue sample prospectively collect tumor tissue sample . Whole blood sample also collect longitudinally Interim visit 5 year . Interim visit schedule dictate physician 's standard-of-care management protocol . No 100mL blood collect per month . Tumor tissue recurrence collect duration subject participation ( Baseline Visit ) .</detailed_description>
	<criteria>Subject 18 year age old ; Subject willing provide write informed consent ; Subject diagnosis nonhematologic cancer , tumor body , either ; 1. residual tumor tissue available test Sponsor ; 2. genomic profiling result IVD LDT assay perform tumor biopsy tissue ; 3. invasive procedure ( biopsy , surgery ) schedule follow Baseline Visit residual tumor tissue available test Sponsor . Subject able , professional opinion investigator , provide whole blood Baseline Visit Interim Visits . Underwent curativeintent surgery management presently diagnose tumor , time prior Baseline Visit . Underwent target nontargeted chemotherapy , hormone receptor block therapy , radiation therapy prior Baseline Visit . Underwent invasive procedure ( biopsy , surgery , thermal ablation ) 7 day prior blood collection ( baseline followup ) . Any medical mental condition would interfere subject ' ability willingly give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>